Outlook Therapeutics, Inc. (OTLK): Revenue

Annual figures by period end, from SEC filings.

$1.41M

Year ended 2025-09-30

Period ended	Revenue	Change YoY	Source filing
2025-09-30	$1.41M	n/a	2025-12-19, From 2024-10-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	$1.41M	n/a
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	$1.31M	+99.2%
Inhibrx Biosciences, Inc. (INBX)	2025-12-31	$1.30M	+550.0%
Pluri Inc. (PLUR)	2026-06-30	$1.02M	-24.0%
Humacyte, Inc. (HUMA)	2025-12-31	$2.04M	n/a
Aligos Therapeutics, Inc. (ALGS)	2025-12-31	$2.19M	-39.5%
Prokidney Corp. (PROK)	2025-12-31	$893.0K	n/m
ImageneBio, Inc. (IMA)	2025-12-31	$800.0K	-77.1%
Dyadic International Inc (DYAI)	2025-12-31	$3.09M	-11.6%

Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗